Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 10,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $17.66, for a total transaction of $176,600.00. Following the completion of the sale, the insider now owns 183,266 shares of the company’s stock, valued at $3,236,477.56. This trade represents a 5.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Centessa Pharmaceuticals Stock Up 1.7 %

Shares of CNTA stock opened at $17.60 on Thursday. Centessa Pharmaceuticals plc has a 1-year low of $5.58 and a 1-year high of $18.74. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market cap of $2.32 billion, a price-to-earnings ratio of -11.50 and a beta of 1.47. The stock’s fifty day moving average price is $16.13 and its 200 day moving average price is $12.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its position in Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after acquiring an additional 418,615 shares during the period. Artal Group S.A. raised its stake in shares of Centessa Pharmaceuticals by 39.5% in the first quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after purchasing an additional 400,000 shares during the last quarter. Farallon Capital Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter worth about $4,192,000. Lynx1 Capital Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter worth about $197,000. Finally, HighMark Wealth Management LLC purchased a new stake in Centessa Pharmaceuticals in the second quarter valued at approximately $840,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CNTA. BMO Capital Markets lifted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Jefferies Financial Group upped their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Guggenheim upped their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Oppenheimer restated an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.